Sildenafil topical - Dar Bioscience/Strategic Science and Technologies

Drug Profile

Sildenafil topical - Dar Bioscience/Strategic Science and Technologies

Alternative Names: SST-6007

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Strategic Science & Technologies
  • Class Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Type 2 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Female sexual dysfunction

Most Recent Events

  • 27 Mar 2018 Chemical structure information added
  • 19 Feb 2018 Dare Biosciences plans phase III trials in Female sexual dysfunction (Dare Biosciences website, February 2018)
  • 12 Feb 2018 Sildenafil topical cream (5%) licensed to Dar Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top